Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.40 |
| ▸ | KDM1A | O60341 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.40 |
| ▸ | PRNP | P04156 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD5 | P21918 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4692952 | 0.93 | KDM1A (0.38) | CYP2D6CYP1A2KDM1ACYP2C19HTR1A | |
| SCHEMBL4694103 | 0.86 | L3MBTL1 (0.39) | CYP2D6CYP1A2KDM1ACYP2C19HTR1A | |
| SCHEMBL4695790 | 0.83 | MEN1 (0.32) | CYP2D6CYP1A2KDM1ACYP2C19HTR1A | |
| SCHEMBL4697388 | 0.82 | CACNA1B (0.36) | HTR1ADRD2CHRM2ADRA2ADRD1 | |
| SCHEMBL4693276 | 0.79 | LMNA (0.35) | CYP2D6CYP1A2KDM1ACYP2C19HTR1A | |
| SCHEMBL4695753 | 0.79 | L3MBTL1 (0.40) | KDM1AHTR6SIGMAR1ADRB2TSHR | |
| SCHEMBL3882159 | 0.77 | CYP2D6 (0.42) | CYP2D6CYP1A2KDM1ACYP2C19HTR1A | |
| SCHEMBL4696480 | 0.76 | BCHE (0.32) | KDM1AHTR1ADRD2CHRM2CHRM4 | |
| SCHEMBL5245045 | 0.76 | NPY5R (0.45) | CYP2D6CYP1A2KDM1ACYP2C19HTR1A | |
| SCHEMBL4693882 | 0.75 | LMNA (0.39) | CYP2D6CYP1A2KDM1ACYP2C19HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509528-B1 | 1,3-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2008-09-24 | — | — | EP | claimed |
| EP-1684749-B1 | USE OF 1,3-DIAZA-DIBENZO[e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-05 | — | — | EP | claimed |
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-06-07 | — | — | US | claimed |
| US-7166583-B2 | 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-01-23 | — | — | US | claimed |
| EP-1684749-B1 | USE OF 1,3-DIAZA-DIBENZO[e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-05 | — | — | EP | disclosed |
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, BCHE, DDT | CYP2D6 578/4885CYP1A2 611/4885KDM1A 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.